Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Onalespib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 19/20 | 1.00 |
| ▸ | HSP90AB1 known ✓ | P08238 | 9/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onalespib SCHEMBL29351356 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL1206927 | 0.99 | HSP90AA1 (0.98) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL1205801 | 0.99 | HSP90AA1 (0.98) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL1207369 | 0.96 | HSP90AA1 (0.92) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL30631701 | 0.95 | HSP90AA1 (0.91) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1205611 | 0.93 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL22548228 | 0.92 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL18546666 | 0.92 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL384367 | 0.92 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL31108363 | 0.90 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-2073803-B1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2018-09-19 | — | — | EP | claimed |
| US-20180169117-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUTED PHENYL - (1,3-DIHYDRO-ISOINDOL-2-YL) - METHANONE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | claimed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | claimed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | claimed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | claimed |
| EP-3119398-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUED PHENYL- (1, 3-DIHYDRO-ISOINDOL-2-YL) -METHANONE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140624-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUED PHENYL- (1, 3-DIHYDRO-ISOINDOL-2-YL) -METHANONE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | WO | claimed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | claimed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| CN-101193862-A | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2008-06-04 | — | — | CN | claimed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | claimed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169117-A1 | PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUTED PHENYL - (1,3-DIHYDRO-ISOINDOL-2-YL) - METHANONE | SDHA, LDHA, ALDH5A1 | HSP90AA1 2185/4885HSP90AB1 2555/4885HSP90B1 2642/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885HSP90B1 11/4885 |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.